CTLA4 and central nervous system cancer: Immune checkpoint blockade such as programmed cell death 1 ligand (PD-L1), indolamine 2,3-dioxygenase (IDO), and cytotoxic T lymphocyte associated antigen 4 (CTLA4), appears to be a potential therapeutic treatment for glioma [5].